This database contains 1041 studies, archived under the term: "male"
Click here to filter this large number of results.
Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer’s disease
Farlow, Martin,
Veloso, Felix,
Moline, Margaret,
Yardley, Jane,
Brand-Schieber, Elimor,
Bibbiani, Francesco,
Zou, Heng,
Hsu, Timothy,
Satlin, Andrew
Background: Donepezil 23 mg/d, recently approved in the United States for treatment of moderate to severe Alzheimer’s disease (AD), was developed to address the need for an additional treatment option for patients with advanced AD. This report, based on a pivotal phase 3 study, presents a detailed analysis of the safety and tolerability of increasing […]
Multifactorial fall prevention for pairs of frail community-dwelling older fallers and their informal caregivers: a dead end for complex interventions in the frailest fallers
Faes, Miriam C.,
Reelick, Miriam F.,
Melis, René J.,
Borm, George F.,
Esselink, Rianne A.,
Rikkert, Marcel G. Olde
Objective: To assess whether a multifactorial fall prevention program was more effective than usual geriatric care in preventing falls and reducing fear of falling in frail community-dwelling older fallers, with and without cognitive impairment, and in alleviating subjective caregiver burden in caregivers.; Design, Setting, and Participants: A randomized, 2 parallel-group, single-blind, multicenter trial conducted in […]
Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer’s disease study ± 2 (DIADS-2)?
Drye, Lea T.,
Martin, Barbara K.,
Frangakis, Constantine E.,
Meinert, Curtis L.,
Mintzer, Jacobo E.,
Munro, Cynthia A.,
Porsteinsson, Anton P.,
Rabins, Peter V.,
Rosenberg, Paul B.,
Schneider, Lon S.,
Weintraub, Daniel,
Lyketsos, Constantine G.
Objective: To determine if the effect of sertraline in the depression in Alzheimer’s disease study – 2 (DIADS-2) differed in subgroups of patients defined by baseline depression criteria.; Methods: DIADS-2 was a randomized, parallel, placebo-controlled, multicenter trial designed to evaluate the efficacy and safety of sertraline (target dose of 100 mg/day) for the treatment of depression […]
Pridopidine for the treatment of motor function in patients with Huntington’s disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial
de Yebenes, Justo Garcia,
Landwehrmeyer, Bernhard,
Squitieri, Ferdinando,
Reilmann, Ralf,
Rosser, Anne,
Barker, Roger A,
Saft, Carsten,
Magnet, Markus K.,
Sword, Alastair,
Rembratt, Åsa,
Tedroff, Joakim
Background: Huntington’s disease is a progressive neurodegenerative disorder, characterised by motor, cognitive, and behavioural deficits. Pridopidine belongs to a new class of compounds known as dopaminergic stabilisers, and results from a small phase 2 study in patients with Huntington’s disease suggested that this drug might improve voluntary motor function. We aimed to assess further the […]
The impact of stimuli on affect in persons with dementia
Objective: To examine how presentation of different stimuli impacts affect in nursing home residents with dementia.; Method: Participants were 193 residents aged 60 to 101 years from 7 Maryland nursing homes who had a diagnosis of dementia (derived from the medical chart or obtained from the attending physician). Cognitive functioning was assessed via the Mini-Mental […]
The effects of exposure to scenarios about dementia on stigma and attitudes toward dementia care in a Chinese community
Cheng, Sheung-Tak,
Lam, Linda C. W.,
Chan, Liliane C. K.,
Law, Alexander C. B.,
Fung, Ada W. T.,
Chan, Wai-chi,
Tam, Cindy W. C.,
Chan, Wai-man
Background: This study investigated whether brief exposure to information has any effect on stigmatizing attitudes towards older people with dementia, and how people responded to this medical diagnosis.; Methods: 494 adults were randomly assigned to three groups differentiated by experimental conditions. Group A (control) responded to questions on stigma directly. Group B (symptom) read two […]
A double-blind placebo-controlled randomized trial of Melissa officinalis oil and donepezil for the treatment of agitation in Alzheimer’s disease
Burns, Alistair,
Perry, Elaine,
Holmes, Clive,
Francis, Paul,
Morris, Julie,
Howes, Melanie-Jayne R.,
Chazot, Paul,
Lees, George,
Ballard, Clive
Background/aims: Behavioural and psychological symptoms (BPSD) are frequent in people with Alzheimer’s disease and cause considerable stress to patients and their carers. Antipsychotics have been widely used as a first-line treatment, resulting in an estimated 1,800 excess strokes and 1,600 excess deaths in the UK alone. Safe and effective alternatives are urgently needed. Based upon […]